Rhesus disease: a global prevention strategy.

Abstract

After nearly five decades of effective prophylaxis in high-income countries, the incidence of rhesus haemolytic disease (also known as haemolytic disease of the fetus and newborn) has substantially decreased, and as a result, clinical experience of the disease among health-care providers is insufficient. By contrast, a worldwide study found that rhesus haemolytic disease continues to be a public health problem in low-income and middle-income countries, affecting annually in more than 150 000 children, and causing thousands of stillbirths, neonatal deaths, and cases of hyperbilirubinaemia with its sequelae (kernicterus and bilirubin-induced neurological dysfunction). Solutions to this problem will require the combined and integrated effort of physicians and other health-care workers, international agencies, manufacturers of the prophylactic agent (rhesus immunoglobulin), health policy makers, and governments of low-income and middle-income countries.

• Authors: Alvin Zipursky, Vinod K Bhutani, Isaac Odame
• Journal: The Lancet. Child & adolescent health (Lancet Child Adolesc Health) Vol. 2 Issue 7 Pg. 536-542 (07 2018) ISSN: 2352-4650 [Electronic] England
• PMID: 30169325 (Publication Type: Journal Article)
• Copyright: Copyright © 2018 Elsevier Ltd. All rights reserved.

Topics

• Erythroblastosis, Fetal (epidemiology, prevention & control)
• Global Health
• Humans
• Infant, Newborn